[go: up one dir, main page]

UY32131A - Compuestos de anillo fusionado y uso de los mismos - Google Patents

Compuestos de anillo fusionado y uso de los mismos

Info

Publication number
UY32131A
UY32131A UY0001032131A UY32131A UY32131A UY 32131 A UY32131 A UY 32131A UY 0001032131 A UY0001032131 A UY 0001032131A UY 32131 A UY32131 A UY 32131A UY 32131 A UY32131 A UY 32131A
Authority
UY
Uruguay
Prior art keywords
fusioned
same
ring compounds
present
glucokinase activator
Prior art date
Application number
UY0001032131A
Other languages
English (en)
Inventor
Yasuma Tsuneo
Takakura Nobuyuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY32131A publication Critical patent/UY32131A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención apunta a proveer un activador de glucoquinasa útil como agente farmacéutico tal como un agente para la profilaxis o el tratamiento de diabetes, obesidad y similares. La presente invención provee un activador de glucoquinasa que contiene un compuesto representado por la fórmula (I) : donde cada símbolo se define en la memoria descriptiva, o una sal del mismo o una prodroga del mismo.
UY0001032131A 2008-04-10 2009-09-21 Compuestos de anillo fusionado y uso de los mismos UY32131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008102691 2008-04-10
PCT/JP2009/057625 WO2009125873A1 (en) 2008-04-10 2009-04-09 Fused ring compounds and use thereof

Publications (1)

Publication Number Publication Date
UY32131A true UY32131A (es) 2010-11-30

Family

ID=40671202

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032131A UY32131A (es) 2008-04-10 2009-09-21 Compuestos de anillo fusionado y uso de los mismos

Country Status (34)

Country Link
US (1) US8673942B2 (es)
EP (1) EP2276760B1 (es)
JP (1) JP5528348B2 (es)
KR (1) KR20110002472A (es)
CN (1) CN102056924B (es)
AR (1) AR073609A1 (es)
AU (1) AU2009234666B2 (es)
BR (1) BRPI0910912A2 (es)
CA (1) CA2720686A1 (es)
CO (1) CO6321240A2 (es)
CR (1) CR11730A (es)
CY (1) CY1115247T1 (es)
DK (1) DK2276760T3 (es)
DO (1) DOP2010000301A (es)
EA (1) EA019640B1 (es)
EC (1) ECSP10010602A (es)
ES (1) ES2476265T3 (es)
GE (1) GEP20135846B (es)
HR (1) HRP20140588T1 (es)
IL (1) IL208463A (es)
MA (1) MA32283B1 (es)
ME (1) ME01887B (es)
MX (1) MX2010011138A (es)
MY (1) MY152475A (es)
NZ (1) NZ588562A (es)
PE (1) PE20100734A1 (es)
PL (1) PL2276760T3 (es)
PT (1) PT2276760E (es)
RS (1) RS53378B (es)
SI (1) SI2276760T1 (es)
UA (1) UA104422C2 (es)
UY (1) UY32131A (es)
WO (1) WO2009125873A1 (es)
ZA (1) ZA201007682B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010076884A1 (ja) 2008-12-29 2012-06-21 武田薬品工業株式会社 新規縮合環化合物およびその用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
WO2014099578A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505612A (ja) 1991-03-01 1993-08-19 ハー・ルンドベック・アクティーゼルスカブ 高血圧症及び末梢血管疾患の治療法
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
EP1510207A4 (en) 2002-06-05 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC MEDICAMENT AGAINST DIABETES
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
WO2006089397A1 (en) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
WO2006112549A1 (ja) * 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited 縮合複素環化合物
WO2007037534A1 (ja) * 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. ２－へテロアリール置換インドール誘導体
MY158052A (en) 2006-10-19 2016-08-30 Takeda Pharmaceutical Indole compound
KR20090018593A (ko) * 2007-08-17 2009-02-20 주식회사 엘지생명과학 세포괴사 저해제로서의 인돌 및 인다졸 화합물
RU2450001C2 (ru) * 2007-12-20 2012-05-10 Эл Джи Лайф Сайенсиз Лтд. Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента
WO2009088192A2 (ko) 2008-01-04 2009-07-16 Lg Life Sciences Ltd. 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체
JPWO2010076884A1 (ja) 2008-12-29 2012-06-21 武田薬品工業株式会社 新規縮合環化合物およびその用途

Also Published As

Publication number Publication date
EP2276760A1 (en) 2011-01-26
WO2009125873A1 (en) 2009-10-15
MY152475A (en) 2014-10-15
JP2011516403A (ja) 2011-05-26
EA019640B1 (ru) 2014-05-30
BRPI0910912A2 (pt) 2015-08-11
UA104422C2 (uk) 2014-02-10
KR20110002472A (ko) 2011-01-07
MX2010011138A (es) 2010-11-12
HK1152932A1 (en) 2012-03-16
CO6321240A2 (es) 2011-09-20
NZ588562A (en) 2012-07-27
IL208463A0 (en) 2010-12-30
ME01887B (me) 2014-12-20
AU2009234666A1 (en) 2009-10-15
HRP20140588T1 (hr) 2014-08-01
IL208463A (en) 2015-07-30
GEP20135846B (en) 2013-06-10
AR073609A1 (es) 2010-11-17
US20110098297A1 (en) 2011-04-28
SI2276760T1 (sl) 2014-05-30
AU2009234666B2 (en) 2014-02-20
RS53378B (sr) 2014-10-31
DOP2010000301A (es) 2010-12-31
PE20100734A1 (es) 2010-11-18
JP5528348B2 (ja) 2014-06-25
ZA201007682B (en) 2011-12-28
PL2276760T3 (pl) 2014-09-30
EA201071180A1 (ru) 2011-04-29
DK2276760T3 (da) 2014-05-26
PT2276760E (pt) 2014-05-28
CA2720686A1 (en) 2009-10-15
CY1115247T1 (el) 2017-01-04
ECSP10010602A (es) 2011-03-31
EP2276760B1 (en) 2014-04-09
CR11730A (es) 2010-12-08
ES2476265T3 (es) 2014-07-14
CN102056924A (zh) 2011-05-11
MA32283B1 (fr) 2011-05-02
CN102056924B (zh) 2014-05-21
US8673942B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
ECSP099330A (es) Compuesto de indol
CR10564A (es) Compuestos cíclicos fusionados
DOP2010000267A (es) Compuesto heterociclico
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
ECSP11011470A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
ECSP13012719A (es) Compuesto bicíclico
ECSP12011573A (es) Compuestos tetracíclicos
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
ECSP11011558A (es) Nuevos compuestos químicos.
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CO6640253A2 (es) Derivados de compuesto biciclico y su uso como inhibidores de acc
CL2008003639A1 (es) Compuestos derivados de amida; composición farmacéutica que comprende a dicho compuesto; combinación farmacéutica; y uso del compuesto en el tratamiento del vih.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181114